Comparative Pharmacology
Head-to-head clinical analysis: FLUNISOLIDE versus HYDROCORTISONE AND ACETIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUNISOLIDE versus HYDROCORTISONE AND ACETIC ACID.
FLUNISOLIDE vs HYDROCORTISONE AND ACETIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory action; inhibits release of inflammatory mediators (e.g., histamine, leukotrienes), reduces eosinophil migration, and stabilizes mast cells. Suppresses cytokine production and adhesion molecule expression.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to increased lipocortin synthesis, inhibition of phospholipase A2, decreased arachidonic acid release, and reduced prostaglandin and leukotriene production; it also suppresses cytokine expression and immune cell migration. Acetic acid is a weak acid that lowers local pH, inhibiting bacterial and fungal growth and disrupting microbial cell membranes.
50 mcg per nostril twice daily (total daily dose 200 mcg), via nasal spray.
Instill 5 drops into affected ear(s) twice daily for 7-10 days; or as directed by physician.
None Documented
None Documented
Clinical Note
moderateFlunisolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Gatifloxacin."
Clinical Note
moderateFlunisolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin."
Clinical Note
moderateFlunisolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin."
Clinical Note
moderateFlunisolide + Trovafloxacin
Terminal elimination half-life is 1.8 hours (range 1.3–2.5 h) after intravenous administration; clinically, endogenous suppression persists up to 24 h post-inhalation.
Plasma t1/2: 1.5-2 hours; biological t1/2: 8-12 hours (based on HPA axis suppression).
Renal (50%) as metabolites, fecal (40%) as metabolites via bile, <5% unchanged in urine.
Renal: ~60-70% as metabolites; biliary/fecal: ~10-15%; unchanged drug: <5%.
Category C
Category D/X
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Trovafloxacin."